Ani Pharmaceutic Stock Price, News & Analysis

ANI Pharmaceuticals (NASDAQ: ANIP) has announced that CEO Nikhil Lalwani will present at the upcoming 2025 Jefferies Global Healthcare Conference in New York City. The presentation is scheduled for Wednesday, June 4, 2025, at 2:35 PM ET.

Investors can access the live and archived webcast through ANI Pharmaceuticals' website at www.anipharmaceuticals.com in the Investors section under Events and Presentations. The webcast replay will be available for 60 days after the event. Interested parties can schedule one-on-one meetings with the company by contacting their Jefferies representative.

ANI Pharmaceuticals (NASDAQ: ANIP) has announced its participation in the upcoming H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ. The company's presentation is scheduled for Tuesday, May 20, 2025, at 1:30pm ET. CEO Nikhil Lalwani and CFO Stephen Carey will represent the company at the conference.

Investors can access the presentation through a live webcast on ANI's website under the Investors section. The webcast recording will remain available for 90 days after the event. One-on-one meetings with management can be arranged through meetings@hcwco.com.

ANI Pharmaceuticals (NASDAQ: ANIP) presented preclinical data on Purified Cortrophin® Gel in an experimental autoimmune uveitis (EAU) mouse model at the ARVO 2025 annual meeting. The study demonstrated that Cortrophin Gel showed a significant dose-dependent effect in suppressing EAU across all tested doses (4, 40, 160, and 400 U/kg), with the strongest suppression at 400 U/kg.

Key findings revealed that the treatment suppressed inflammatory cytokine production and reduced retinal damage caused by EAU, comparable to α-MSH treatment versus placebo. The research supports the company's understanding of Cortrophin Gel's mechanism of action and demonstrates ANI's commitment to expanding clinical research for their products.

ANI Pharmaceuticals (NASDAQ: ANIP) has scheduled its first quarter 2025 financial results announcement for Friday, May 9, 2025, before market opening. The company will host a conference call at 8:00 a.m. ET to discuss the results.

Key executives participating in the call include President and CEO Nikhil Lalwani, SVP Finance and CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz. Investors can access the call via toll-free number 800-225-9448 using Conference ID 4921902.

The webcast will be available live and for replay on the company's website under the Investors section. A replay option will be accessible for two weeks by calling 800-753-8591 with access code 4921902.

ANI Pharmaceuticals (ANIP) has announced its participation in the upcoming 2025 RBC Capital Markets Ophthalmology Virtual Conference. The company's President and CEO, Nikhil Lalwani, will conduct a fireside chat during the event.

The presentation will be available through a live and archived webcast on the company's website www.anipharmaceuticals.com under the Investors section's Events and Presentations area. Interested parties can access the webcast replay for 60 days following the event.

ANI Pharmaceuticals (Nasdaq: ANIP) has announced the launch of Nitazoxanide Tablets, 500 mg, a generic version of the reference listed drug Alinia®. This launch represents another addition to ANI's portfolio of niche competition products.

The company has partnered with Biophore for this product launch, aiming to provide affordable, high-quality medicines to patients. According to IQVIA data from December 2024, the U.S. annual sales for Nitazoxanide Tablets amount to approximately $36.1 million.

ANI Pharmaceuticals (ANIP) has announced the completion of a buyout of its 3.125% perpetual royalty obligation to SWK Funding for ILUVIEN® and YUTIQ® products. The company made a one-time payment of $17.25 million, funded through cash on hand, eliminating future royalty payments on worldwide net revenues effective January 1, 2025.

According to CEO Nikhil Lalwani, this strategic move demonstrates ANI's commitment to strengthening its Retina portfolio while enhancing financial flexibility and growth potential for these key products.

ANI Pharmaceuticals (ANIP) has received FDA approval for an expanded label of ILUVIEN (fluocinolone acetonide intravitreal implant) to include treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS), in addition to its existing diabetic macular edema (DME) indication.

The company plans to market ILUVIEN for both indications in the U.S. later this year. The treatment is already approved for both DME and NIU-PS in seventeen European countries. ANI has extended its supply agreement with Siegfried through 2029, including plans to upgrade equipment and expand manufacturing capacity.

ILUVIEN is specifically indicated for DME patients previously treated with corticosteroids without significant intraocular pressure rise, and for chronic NIU-PS treatment. The treatment carries important safety considerations, including risks of infection, increased intraocular pressure, cataracts, and delayed wound healing.